Cargando…

Atorvastatin May Attenuate Recurrence of Chronic Subdural Hematoma

Objective: Chronic subdural hematoma (CSDH) is a common form of intracranial hemorrhage with a substantial recurrence rate. Atorvastatin may reduce CSDH via its anti-inflammatory and pro-angiogenesis effects, but its effectiveness for preventing recurrent CSDH has never been explored. We hypothesize...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hua, Luo, Zhengxiang, Liu, Zhongkun, Yang, Jian, Kan, Shifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923224/
https://www.ncbi.nlm.nih.gov/pubmed/27445673
http://dx.doi.org/10.3389/fnins.2016.00303
_version_ 1782439704613879808
author Liu, Hua
Luo, Zhengxiang
Liu, Zhongkun
Yang, Jian
Kan, Shifeng
author_facet Liu, Hua
Luo, Zhengxiang
Liu, Zhongkun
Yang, Jian
Kan, Shifeng
author_sort Liu, Hua
collection PubMed
description Objective: Chronic subdural hematoma (CSDH) is a common form of intracranial hemorrhage with a substantial recurrence rate. Atorvastatin may reduce CSDH via its anti-inflammatory and pro-angiogenesis effects, but its effectiveness for preventing recurrent CSDH has never been explored. We hypothesized that atorvastatin is effective in reducing recurrence of CSDH after surgery and identified determining factors predictive of hematoma recurrence. Methods: A prospective study was conducted in 168 surgical cases of CSDH.All patients were randomly assigned to the group treated with atorvastatin or control group. Clinically relevant data were compared between two groups, and subsequently between the recurrence and non-recurrence patients. Multiple logistic regression analysis of the relationship between atorvastatin treatment and the recurrence using brain atrophy, septated and bilateral hematoma was performed. Results: Atorvastatin group conferred an advantage by significantly decreasing the recurrence rate (P = 0.023), and patients managed with atorvastatin also had a longer time-to-recurrence (P = 0.038). Admission brain atrophy and bilateral hematoma differed significantly between the recurrence and non-recurrence patients (P = 0.047 and P = 0.045). The results of logistic regression analysis showed that atorvastatin significantly reduced the probability of recurrence; severe brain atrophy and bilateral hematoma were independent risk factors for recurrent CSDH. Conclusions: Atorvastatin administration may decrease the risks of recurrence.Patients with severe brain atrophy and bilateral CSDH are prone to the recurrence.
format Online
Article
Text
id pubmed-4923224
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-49232242016-07-21 Atorvastatin May Attenuate Recurrence of Chronic Subdural Hematoma Liu, Hua Luo, Zhengxiang Liu, Zhongkun Yang, Jian Kan, Shifeng Front Neurosci Pharmacology Objective: Chronic subdural hematoma (CSDH) is a common form of intracranial hemorrhage with a substantial recurrence rate. Atorvastatin may reduce CSDH via its anti-inflammatory and pro-angiogenesis effects, but its effectiveness for preventing recurrent CSDH has never been explored. We hypothesized that atorvastatin is effective in reducing recurrence of CSDH after surgery and identified determining factors predictive of hematoma recurrence. Methods: A prospective study was conducted in 168 surgical cases of CSDH.All patients were randomly assigned to the group treated with atorvastatin or control group. Clinically relevant data were compared between two groups, and subsequently between the recurrence and non-recurrence patients. Multiple logistic regression analysis of the relationship between atorvastatin treatment and the recurrence using brain atrophy, septated and bilateral hematoma was performed. Results: Atorvastatin group conferred an advantage by significantly decreasing the recurrence rate (P = 0.023), and patients managed with atorvastatin also had a longer time-to-recurrence (P = 0.038). Admission brain atrophy and bilateral hematoma differed significantly between the recurrence and non-recurrence patients (P = 0.047 and P = 0.045). The results of logistic regression analysis showed that atorvastatin significantly reduced the probability of recurrence; severe brain atrophy and bilateral hematoma were independent risk factors for recurrent CSDH. Conclusions: Atorvastatin administration may decrease the risks of recurrence.Patients with severe brain atrophy and bilateral CSDH are prone to the recurrence. Frontiers Media S.A. 2016-06-28 /pmc/articles/PMC4923224/ /pubmed/27445673 http://dx.doi.org/10.3389/fnins.2016.00303 Text en Copyright © 2016 Liu, Luo, Liu, Yang and Kan. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Liu, Hua
Luo, Zhengxiang
Liu, Zhongkun
Yang, Jian
Kan, Shifeng
Atorvastatin May Attenuate Recurrence of Chronic Subdural Hematoma
title Atorvastatin May Attenuate Recurrence of Chronic Subdural Hematoma
title_full Atorvastatin May Attenuate Recurrence of Chronic Subdural Hematoma
title_fullStr Atorvastatin May Attenuate Recurrence of Chronic Subdural Hematoma
title_full_unstemmed Atorvastatin May Attenuate Recurrence of Chronic Subdural Hematoma
title_short Atorvastatin May Attenuate Recurrence of Chronic Subdural Hematoma
title_sort atorvastatin may attenuate recurrence of chronic subdural hematoma
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923224/
https://www.ncbi.nlm.nih.gov/pubmed/27445673
http://dx.doi.org/10.3389/fnins.2016.00303
work_keys_str_mv AT liuhua atorvastatinmayattenuaterecurrenceofchronicsubduralhematoma
AT luozhengxiang atorvastatinmayattenuaterecurrenceofchronicsubduralhematoma
AT liuzhongkun atorvastatinmayattenuaterecurrenceofchronicsubduralhematoma
AT yangjian atorvastatinmayattenuaterecurrenceofchronicsubduralhematoma
AT kanshifeng atorvastatinmayattenuaterecurrenceofchronicsubduralhematoma